Marieke van Son

189 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 54. Zaorsky NG, Keith SW, Shaikh T, Nguyen PL, Horwitz EM, Dicker AP, et al. Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxici- ties. Am J Clin Oncol. 2018;41(4):409-15. 55. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Ran- domized Clinical Trial. JAMA oncology. 2018;4(6):e180039. 56. Kerkmeijer LGW, Groen VH, Pos FJ, Haus- termans K, Monninkhof EM, Smeenk RJ, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiothera- py for Patients With Localized Pros- tate Cancer: Results From the FLAME Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021:JCO2002873. 57. Spratt DE, Michalski JM. Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019;104(4):798-800. 58. Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, et al. Long-term Outcomes of Stereotactic Body Radio- therapy for Low-Risk and Intermedi- ate-Risk Prostate Cancer. JAMA Netw Open. 2019;2(2):e188006. 59. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-mod- ulated fractionated radiotherapy versus stereotactic body radiotherapy for pros- tate cancer (PACE-B): acute toxicity find- ings from an international, randomised, open-label, phase 3, non-inferiority trial. The Lancet Oncology. 2019;20(11):1531-43. 60. Pathmanathan AU, van As NJ, Kerkmei- jer LGW, Christodouleas J, Lawton CAF, Vesprini D, et al. Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A “Game Changer” for Prostate Treatment? Int J Radiat Oncol Biol Phys. 2018;100(2):361-73. 61. Morton G, McGuffin M, Chung HT, Tseng CL, Helou J, Ravi A, et al. Prostate high dose-rate brachytherapy as monothera- py for low and intermediate risk prostate cancer: Efficacy results from a random- ized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Ra- diother Oncol. 2020;146:90-6. 62. Murgic J, Morton G, Loblaw A, D’Ali- monte L, Ravi A, Wronski M, et al. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Fail- ure: Results From a Prospective Clini- cal Trial. Int J Radiat Oncol Biol Phys. 2018;102(3):561-7. 63. Jiang P, van der Horst C, Kimmig B, Zins- ser F, Poppe B, Luetzen U, et al. Inter- stitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome. Brachytherapy. 2017;16(1):186-92. 64. Slevin F, Hodgson S, Rodda SL, Bownes P, Bottomley D, Adiotomre E, et al. Effi- cacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent pros- tate cancer. Clinical and translational ra- diation oncology. 2020;23:20-6. 65. Chitmanee P, Tsang Y, Tharmalingam H, Hamada M, Alonzi R, Ostler P, et al. Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recur- rent Prostate Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2020;32(4):259-65. 66. van Son M, Peters M, Moerland M, van de Pol S, Eppinga W, Lagendijk J, et al. Determining the safety of ultrafocal sal- vage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxic- ity assessment of 150 patients. Clinical and translational radiation oncology. 2021;27:1-7. 10